Modulation of T-effector function by imatinib at the level of cytokine secretion

Experimental Hematology

Volumn 35, Issue 8, 2007, Pages 1266-1271

  Leder, Christoph ^a   Ortler, Sonja ^a   Seggewiss, Ruth ^a   Einsele, Hermann ^a   Wiendl, Heinz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; IMATINIB;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOMODULATION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; MICE; MICE, INBRED C57BL; PIPERAZINES; PYRIMIDINES; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34447639395     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.04.016     Document Type: Article

References (28)

1. Druker B.J., and Lydon N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105 (2000) 3-7
2. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
3. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
4. Deininger M.W., Goldman J.M., Lydon N., and Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90 (1997) 3691-3698
5. Gambacorti-Passerini C., le Coutre P., Mologni L., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23 (1997) 380-394
6. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
7. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
8. Carroll M., Ohno-Jones S., Tamura S., et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90 (1997) 4947-4952
9. Fabian M.A., Biggs III W.H., Treiber D.K., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 (2005) 329-336
10. Koretzky G.A., Abtahian F., and Silverman M.A. SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol 6 (2006) 67-78
11. Seggewiss R., Lore K., Greiner E., et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105 (2005) 2473-2479
12. Dietz A.B., Souan L., Knutson G.J., Bulur P.A., Litzow M.R., and Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104 (2004) 1094-1099
13. Cwynarski K., Laylor R., Macchiarulo E., et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18 (2004) 1332-1339
14. Paniagua R.T., Sharpe O., Ho P.P., et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116 (2006) 2633-2642
15. Mumprecht S., Matter M., Pavelic V., and Ochsenbein A.F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108 (2006) 3406-3413
16. Shinkai Y., Rathbun G., Lam K.P., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68 (1992) 855-867
17. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., and Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 76 (1994) 17-27
18. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., and Rammensee H.G. Exact prediction of a natural T cell epitope. Eur J Immunol 21 (1991) 2891-2894
19. Pavlenko M., Leder C., Roos A.K., Levitsky V., and Pisa P. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate 64 (2005) 50-59
20. Sheehy M.E., McDermott A.B., Furlan S.N., Klenerman P., and Nixon D.F. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 249 (2001) 99-110
21. Kayagaki N., Yamaguchi N., Nagao F., et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U S A 94 (1997) 3914-3919
22. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., and Linington C. Animal models. Ann Neurol 36 suppl (1994) S47-S53
23. Bischof F., Hofmann M., Schumacher T.N., et al. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol 172 (2004) 2878-2884
24. Slifka M.K., and Whitton J.L. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol 2 (2001) 711-717
25. Peng B., Hayes M., Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 (2004) 935-942
26. Betts M.R., Price D.A., Brenchley J.M., et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 172 (2004) 6407-6417
27. Baccala R., Kono D.H., and Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204 (2005) 9-26
28. Ozawa M., and Aiba S. Immunopathogenesis of psoriasis. Curr Drug Targets Inflamm Allergy 3 (2004) 137-144